Julia Adriana Kasmirski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia Adriana Kasmirski has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Andrea Gillis
University of Alabama at Birmingham
5 shared publicationsBrenessa Lindeman
University of Alabama at Birmingham
5 shared publicationsHerbert Chen
University of Alabama at Birmingham
4 shared publicationsRaj Roy
University of Alabama at Birmingham
4 shared publicationsChristopher Wu
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA
3 shared publications- Flávio Carneiro Hojaij
Universidade de São Paulo, Brazil
3 shared publications
Latest Publications
- 27 August 2026
- Published by SAGE Publications in The American Surgeon™
Smoking as a Potential Risk Factor for Thyroid Cancer in Patients With Thyroid Nodules
Background: Smoking is a known carcinogen and its relationship with the development of thyroid cancer (TC) is not well established and prior evidence shows a possible protective relationship. We aim to evaluate the impact of smoking on the development of TC. Methods: This is a retrospective cohort study of adult patients who were diagnosed with a thyroid nodule(s) between 2005 and 2025. Cohorts were developed based on smoking status. Patients with the diagnosis of multiple endocrine neoplasia syndrome or who had known TC were excluded. Propensity score matching (PSM) was performed. The primary outcome was diagnosis of TC. Hazard ratios (HRs) and 95% confidence intervals were calculated. Cohorts were then divided into subgroups based on sex and racial groups with the same analysis. Results: There were 404,811 individuals identified who were smokers and had thyroid nodules. Average age was 60 +/− 15 years, with 69% of the cohort being female and 70% white. TC developed in 3.4% of smokers with nodules compared to 1.2% of nonsmokers (HR = 2.60). Subgroup analysis revealed an increased risk across all sex and racial groups. Female smokers had a HR than males at 2.62. Across racial groups, Black patients had the highest HR at 2.91. All groups had confidence intervals that did not cross one. Discussion: In this retrospective cohort study, smoking was significantly associated with an increased risk of developing TC. There was an increased risk of developing TC in all groups, and Black patients had the highest HR highlighting an area that warrants further investigation.
- 27 August 2026
- Published by SAGE Publications in The American Surgeon™
Smoking as a Potential Risk Factor for Thyroid Cancer in Patients With Thyroid Nodules
Background: Smoking is a known carcinogen and its relationship with the development of thyroid cancer (TC) is not well established and prior evidence shows a possible protective relationship. We aim to evaluate the impact of smoking on the development of TC. Methods: This is a retrospective cohort study of adult patients who were diagnosed with a thyroid nodule(s) between 2005 and 2025. Cohorts were developed based on smoking status. Patients with the diagnosis of multiple endocrine neoplasia syndrome or who had known TC were excluded. Propensity score matching (PSM) was performed. The primary outcome was diagnosis of TC. Hazard ratios (HRs) and 95% confidence intervals were calculated. Cohorts were then divided into subgroups based on sex and racial groups with the same analysis. Results: There were 404,811 individuals identified who were smokers and had thyroid nodules. Average age was 60 +/− 15 years, with 69% of the cohort being female and 70% white. TC developed in 3.4% of smokers with nodules compared to 1.2% of nonsmokers (HR = 2.60). Subgroup analysis revealed an increased risk across all sex and racial groups. Female smokers had a HR than males at 2.62. Across racial groups, Black patients had the highest HR at 2.91. All groups had confidence intervals that did not cross one. Discussion: In this retrospective cohort study, smoking was significantly associated with an increased risk of developing TC. There was an increased risk of developing TC in all groups, and Black patients had the highest HR highlighting an area that warrants further investigation.
- 17 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117111
Revealing the sex divide: Primary hyperparathyroidism across the American population
- 17 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117111
Revealing the sex divide: Primary hyperparathyroidism across the American population
- 29 January 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 254, 116854
Surgery for kidney-related hyperparathyroidism: A review
- 29 January 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 254, 116854
Surgery for kidney-related hyperparathyroidism: A review
- 16 September 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 254, 116613
Prevalence of parathyroid multiglandular disease in Asian population
- 16 September 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 254, 116613
Prevalence of parathyroid multiglandular disease in Asian population
- Open Access
- 21 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 8109
Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma—A Systematic Review
Skin cancer is the most common cancer form worldwide, and it is primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent condition. Cutaneous squamous cell carcinoma (cSCC) accounts for 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC’s current standard treatment is surgical resection and chemotherapy. Unfortunately, these methods often lead to disfigurement, functional morbiditly, and compromised function. In contrast to immunotherapy, emerging scenarios have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, NY, USA), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab in the neoadjuvant setting for cSCC treatment. The Methodology followed PRISMA guidelines, this review analyzed studies on Cemiplimab as a neoadjuvant therapy for cSCC that were sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. From 341 records, 21 studies were included, and six clinical trials provided key data about neoadjuvant Cemiplimab’s response rates, efficacy, adverse effects, and safety considerations. The targeted data revealed a neoadjuvant Cemiplimab mean pathologic response rate of 72%, with a 62% objective response rate. Treatment-related adverse events (TRAEs) affect 66% of patients, though most cases are not severe. The most common include fatigue, maculopapular rash, and diarrhea. The studies showed high rates of complete pathological responses (cPRs) and major pathological responses (mPRs), suggesting a strong therapeutic potential. Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. The current literature indicates that Cemiplimab may also be effective when used in immunosuppressed patients. Despite more research still being needed to confirm its long-term benefits and the effects of the drug’s use outside of clinical trials, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment.
- 21 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 8109
Open AccessEfficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma—A Systematic Review
Skin cancer is the most common cancer form worldwide, and it is primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent condition. Cutaneous squamous cell carcinoma (cSCC) accounts for 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC’s current standard treatment is surgical resection and chemotherapy. Unfortunately, these methods often lead to disfigurement, functional morbiditly, and compromised function. In contrast to immunotherapy, emerging scenarios have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, NY, USA), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab in the neoadjuvant setting for cSCC treatment. The Methodology followed PRISMA guidelines, this review analyzed studies on Cemiplimab as a neoadjuvant therapy for cSCC that were sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. From 341 records, 21 studies were included, and six clinical trials provided key data about neoadjuvant Cemiplimab’s response rates, efficacy, adverse effects, and safety considerations. The targeted data revealed a neoadjuvant Cemiplimab mean pathologic response rate of 72%, with a 62% objective response rate. Treatment-related adverse events (TRAEs) affect 66% of patients, though most cases are not severe. The most common include fatigue, maculopapular rash, and diarrhea. The studies showed high rates of complete pathological responses (cPRs) and major pathological responses (mPRs), suggesting a strong therapeutic potential. Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. The current literature indicates that Cemiplimab may also be effective when used in immunosuppressed patients. Despite more research still being needed to confirm its long-term benefits and the effects of the drug’s use outside of clinical trials, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment.
- 29 July 2025
- Published by SAGE Publications in The American Surgeon™
- Vol. 92 (2) , 337-344
Diagnosis and Management Gaps in Tertiary Hyperparathyroidism Following Renal Transplant
Background: Tertiary hyperparathyroidism (3HPT) occurs when hypercalcemia and elevated parathyroid hormone (PTH) persist after renal transplantation. Our study aims to identify gaps in the diagnosis and treatment of patients with 3HPT. Methods: In a single-center retrospective analysis, we identified renal transplant patients with 3HPT based on the history of secondary hyperparathyroidism, preserved renal allograft function, and persistent serum PTH elevations (12-88 pg/mL) during postoperative follow-up. Results: A total of 1556 patients were biochemically diagnosed with 3HPT. Median age was 57 (IQR = 47-65). Most were male (n = 888, 61%), black (n = 801, 55%), and did not undergo parathyroidectomy (n = 1388, 95.4%). Of these, 29.4% (n = 429) of the patients were diagnosed and treated, 23.4% (n = 354) were diagnosed and not treated, and 46.2% (n = 672) remained undiagnosed. Predictive factors for diagnosis and treatment included elevated pre-kidney transplantation PTH levels ≥ 600 pg/mL, postoperative PTH levels ≥ 300 pg/mL, and elevated postoperative calcium (≥10.4 mg/dL). Conclusion: Most patients with biochemical 3HPT remain undiagnosed. This highlights gaps in patient care and the need for clearer guidelines on timing for PTH assessment and surgical referral in patients with 3HPT.
- 29 July 2025
- Published by SAGE Publications in The American Surgeon™
- Vol. 92 (2) , 337-344
Diagnosis and Management Gaps in Tertiary Hyperparathyroidism Following Renal Transplant
Background: Tertiary hyperparathyroidism (3HPT) occurs when hypercalcemia and elevated parathyroid hormone (PTH) persist after renal transplantation. Our study aims to identify gaps in the diagnosis and treatment of patients with 3HPT. Methods: In a single-center retrospective analysis, we identified renal transplant patients with 3HPT based on the history of secondary hyperparathyroidism, preserved renal allograft function, and persistent serum PTH elevations (12-88 pg/mL) during postoperative follow-up. Results: A total of 1556 patients were biochemically diagnosed with 3HPT. Median age was 57 (IQR = 47-65). Most were male (n = 888, 61%), black (n = 801, 55%), and did not undergo parathyroidectomy (n = 1388, 95.4%). Of these, 29.4% (n = 429) of the patients were diagnosed and treated, 23.4% (n = 354) were diagnosed and not treated, and 46.2% (n = 672) remained undiagnosed. Predictive factors for diagnosis and treatment included elevated pre-kidney transplantation PTH levels ≥ 600 pg/mL, postoperative PTH levels ≥ 300 pg/mL, and elevated postoperative calcium (≥10.4 mg/dL). Conclusion: Most patients with biochemical 3HPT remain undiagnosed. This highlights gaps in patient care and the need for clearer guidelines on timing for PTH assessment and surgical referral in patients with 3HPT.
- Open Access
- 14 May 2025
- Published by Associação Catarinense de Medicina in Arquivos Catarinenses de Medicina
- Vol. 54 (1) , 355-358
INTELIGENCIA ARTIFICIAL EM RINOPLASTIA: REVISAO SISTEMATICA APLICADA NA PRATICA CLINICA
Esta revisão sistemática qualitativa avalia as aplicações da inteligência artificial (IA) na rinoplastia. A IA, incluindo aprendizado de máquina (AM) e aprendizado profundo (AP), está transformando a área ao oferecer ferramentas para análise de imagens, simulação de resultados cirúrgicos e auxílio na tomada de decisões. Métodos: Realizou-se uma revisão sistemática seguindo as diretrizes PRISMA, utilizando a ferramenta ROBINS-I para avaliar o risco de viés. A pesquisa incluiu os termos MeSH "Artificial intelligence" OR "Machine Learning" OR "Deep Learning" AND "Rhinoplasty". Resultados: A IA tem aplicações promissoras em rinoplastia. Redes neurais convolucionais (CNNs) são usadas para classificar imagens de rinoplastia e analisar o impacto da cirurgia no envelhecimento facial. Redes generativas adversariais (GANs) permitem a simulação de resultados cirúrgicos realistas. Conclusão: A IA aprimora a precisão e a objetividade na rinoplastia, auxiliando cirurgiões e pacientes no planejamento cirúrgico e na avaliação de resultados.
- 14 May 2025
- Published by Associação Catarinense de Medicina in Arquivos Catarinenses de Medicina
- Vol. 54 (1) , 355-358
Open AccessINTELIGENCIA ARTIFICIAL EM RINOPLASTIA: REVISAO SISTEMATICA APLICADA NA PRATICA CLINICA
Esta revisão sistemática qualitativa avalia as aplicações da inteligência artificial (IA) na rinoplastia. A IA, incluindo aprendizado de máquina (AM) e aprendizado profundo (AP), está transformando a área ao oferecer ferramentas para análise de imagens, simulação de resultados cirúrgicos e auxílio na tomada de decisões. Métodos: Realizou-se uma revisão sistemática seguindo as diretrizes PRISMA, utilizando a ferramenta ROBINS-I para avaliar o risco de viés. A pesquisa incluiu os termos MeSH "Artificial intelligence" OR "Machine Learning" OR "Deep Learning" AND "Rhinoplasty". Resultados: A IA tem aplicações promissoras em rinoplastia. Redes neurais convolucionais (CNNs) são usadas para classificar imagens de rinoplastia e analisar o impacto da cirurgia no envelhecimento facial. Redes generativas adversariais (GANs) permitem a simulação de resultados cirúrgicos realistas. Conclusão: A IA aprimora a precisão e a objetividade na rinoplastia, auxiliando cirurgiões e pacientes no planejamento cirúrgico e na avaliação de resultados.
- Open Access
- 17 March 2025
- Published by MDPI AG in Preprints.org
Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma
Background/Objectives: Skin cancer is the most common cancer worldwide, primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent. Cutaneous squamous cell carcinoma (cSCC) represents 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC current standard treatment is surgical resection and chemotherapy. Unfortunately these methods often lead to disfigurement, functional morbidly and compromised function. In contrast from immunotherapy emerging scenarios that have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, New York, United States), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab neoadjuvant setting on cSCC treatment. Methods: Following PRISMA guidelines, this review analyzed studies on Cemiplimab as neoadjuvant therapy for cSCC, sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. A total of 21 studies were examined, focusing on response rates, adverse effects, and outcomes. Results: From 341 records, 21 studies were included, and six clinical trials provided key data.The targeted data revealed that neoadjuvant Cemiplimab showed a mean pathologic response rate of 72%, with a 62% objective response rate. The most commonly found treatment-related adverse events (TRAEs) included fatigue, maculopapular rash, and diarrhea, affecting 66% of patients, with few severe cases. The studies demonstrated high rates of complete pathological responses (cPR) and major pathological responses (mPR), suggesting a strong therapeutic potential. Conclusions: Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. Despite more research is still needed to confirm its long-term benefits and real-world settings feasibility, some case series already indicate comparable results in immunosuppressed patients. Finally, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment
- 17 March 2025
- Published by MDPI AG in Preprints.org
Open AccessEfficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma
Background/Objectives: Skin cancer is the most common cancer worldwide, primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent. Cutaneous squamous cell carcinoma (cSCC) represents 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC current standard treatment is surgical resection and chemotherapy. Unfortunately these methods often lead to disfigurement, functional morbidly and compromised function. In contrast from immunotherapy emerging scenarios that have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, New York, United States), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab neoadjuvant setting on cSCC treatment. Methods: Following PRISMA guidelines, this review analyzed studies on Cemiplimab as neoadjuvant therapy for cSCC, sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. A total of 21 studies were examined, focusing on response rates, adverse effects, and outcomes. Results: From 341 records, 21 studies were included, and six clinical trials provided key data.The targeted data revealed that neoadjuvant Cemiplimab showed a mean pathologic response rate of 72%, with a 62% objective response rate. The most commonly found treatment-related adverse events (TRAEs) included fatigue, maculopapular rash, and diarrhea, affecting 66% of patients, with few severe cases. The studies demonstrated high rates of complete pathological responses (cPR) and major pathological responses (mPR), suggesting a strong therapeutic potential. Conclusions: Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. Despite more research is still needed to confirm its long-term benefits and real-world settings feasibility, some case series already indicate comparable results in immunosuppressed patients. Finally, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment
- Open Access
- 1 March 2025
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 8, 1
Bibliometric review of journal articles on pancreatic cancer: insights into productivity and impact
Background: Bibliometric review offers a comprehensive and quantitative evaluation of pancreatic cancer research, focusing on journal and author productivity. Despite significant efforts to improve pancreatic cancer outcomes and expand the literature on the topic, there is still insufficient data on influential journals and article impact measures to guide researchers through journal submissions. This article aims to evaluate research productivity and identify influential journals and authors within the field. Utilizing bibliometric indices like impact factor, h-index, and eigenfactor will facilitate the assessment process. Methods: A comprehensive search on July 1, 2023 in the Scopus database to identify articles related to pancreatic cancer. The search criteria included the keyword “Pancreatic Cancer” in the subject area of “Medicine”, limited to English language articles published between January 1989 and December 2022. We calculated publication and citation counts at the article, journal, and first author levels, employing various measures of centrality. Statistical analysis was conducted using the Student t-test. Results: The search yielded 52,154 articles from 3,155 journals with total citations of 1,903,916. The journal with the largest median citations dealing solely with pancreatic cancer was the Annals of Surgery. The journal with the highest number of publications is Pancreas. Six of the top twenty most cited articles were treatment-related articles. Of the top 30 journals by article count, JAMA had the highest median citation count, 340 of 33 articles. The most cited authors list was not associated with high productivity, similarly, the most productive authors were not associated with a high rate of citations. Conclusions: This study offers valuable insights for researchers and institutions in guiding journal selections and themes identified as popular among the research community. It positively impacts the selection of appropriate journals to submit articles on the topic by easily identifying the most impactful and cited journals. The findings emphasize the growing interest in the field, the emergence of specialized journals, and a focus on treatment-related investigations. Overall, this analysis underscores the relevance of bibliometric approaches in advancing pancreatic cancer research.
- 1 March 2025
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 8, 1
Open AccessBibliometric review of journal articles on pancreatic cancer: insights into productivity and impact
Background: Bibliometric review offers a comprehensive and quantitative evaluation of pancreatic cancer research, focusing on journal and author productivity. Despite significant efforts to improve pancreatic cancer outcomes and expand the literature on the topic, there is still insufficient data on influential journals and article impact measures to guide researchers through journal submissions. This article aims to evaluate research productivity and identify influential journals and authors within the field. Utilizing bibliometric indices like impact factor, h-index, and eigenfactor will facilitate the assessment process. Methods: A comprehensive search on July 1, 2023 in the Scopus database to identify articles related to pancreatic cancer. The search criteria included the keyword “Pancreatic Cancer” in the subject area of “Medicine”, limited to English language articles published between January 1989 and December 2022. We calculated publication and citation counts at the article, journal, and first author levels, employing various measures of centrality. Statistical analysis was conducted using the Student t-test. Results: The search yielded 52,154 articles from 3,155 journals with total citations of 1,903,916. The journal with the largest median citations dealing solely with pancreatic cancer was the Annals of Surgery. The journal with the highest number of publications is Pancreas. Six of the top twenty most cited articles were treatment-related articles. Of the top 30 journals by article count, JAMA had the highest median citation count, 340 of 33 articles. The most cited authors list was not associated with high productivity, similarly, the most productive authors were not associated with a high rate of citations. Conclusions: This study offers valuable insights for researchers and institutions in guiding journal selections and themes identified as popular among the research community. It positively impacts the selection of appropriate journals to submit articles on the topic by easily identifying the most impactful and cited journals. The findings emphasize the growing interest in the field, the emergence of specialized journals, and a focus on treatment-related investigations. Overall, this analysis underscores the relevance of bibliometric approaches in advancing pancreatic cancer research.
- Open Access
- 8 January 2025
- Published by Brazilian Journals in STUDIES IN MULTIDISCIPLINARY REVIEW
- Vol. 6 (1) , e14369
The use of fine needle aspiration and frozen section in parotid tumors: a review
Introduction: Parotid gland tumors, although uncommon, present clinical and radiological features that don’t demonstrate their aggressiveness and behavior. Objective: In this study, we aimed to deepen the applicability of Fine Needle Aspiration and Frozen Sections as diagnostic methods. Materials and Methods: A search was conducted in the PubMed, Web of Science, Embase, and Scopus databases using the combination (Frozen Sections) AND (parotid gland) AND ((Surgical Procedures, Operative) OR (Elective Surgical Procedures)). A total of 170 articles were obtained, which underwent a selection based on title and abstract, resulting in 46 articles. From these articles, a second selection was made through complete reading, resulting in 24 articles. Results: 70.83% of the articles reported that Fine Needle Aspiration can provide reliable diagnoses. According to 54.17%, surgical planning can be obtained through Fine Needle Aspiration. No article addressed the chance of recurrences with the use of Fine Needle Aspiration. Frozen Sections can modify surgical planning, as reported in 91.67%. The use of Frozen Sections to modify neck dissection was indicated in 50%. In 8.33%, it was highlighted that Frozen Sections reduce the chance of recurrences. Among the articles that clearly expressed their ideas, 7 out of 11 advocated for the application of Frozen Sections with reservations, while 4 out of 11 supported their routine use. Conclusion: Fine Needle Aspiration is a widely used method for initial evaluations but has limitations in terms of accurate diagnosis and individualized treatment. Frozen Sections are a method that can assist the surgeon in intraoperative decision-making.
- 8 January 2025
- Published by Brazilian Journals in STUDIES IN MULTIDISCIPLINARY REVIEW
- Vol. 6 (1) , e14369
Open AccessThe use of fine needle aspiration and frozen section in parotid tumors: a review
Introduction: Parotid gland tumors, although uncommon, present clinical and radiological features that don’t demonstrate their aggressiveness and behavior. Objective: In this study, we aimed to deepen the applicability of Fine Needle Aspiration and Frozen Sections as diagnostic methods. Materials and Methods: A search was conducted in the PubMed, Web of Science, Embase, and Scopus databases using the combination (Frozen Sections) AND (parotid gland) AND ((Surgical Procedures, Operative) OR (Elective Surgical Procedures)). A total of 170 articles were obtained, which underwent a selection based on title and abstract, resulting in 46 articles. From these articles, a second selection was made through complete reading, resulting in 24 articles. Results: 70.83% of the articles reported that Fine Needle Aspiration can provide reliable diagnoses. According to 54.17%, surgical planning can be obtained through Fine Needle Aspiration. No article addressed the chance of recurrences with the use of Fine Needle Aspiration. Frozen Sections can modify surgical planning, as reported in 91.67%. The use of Frozen Sections to modify neck dissection was indicated in 50%. In 8.33%, it was highlighted that Frozen Sections reduce the chance of recurrences. Among the articles that clearly expressed their ideas, 7 out of 11 advocated for the application of Frozen Sections with reservations, while 4 out of 11 supported their routine use. Conclusion: Fine Needle Aspiration is a widely used method for initial evaluations but has limitations in terms of accurate diagnosis and individualized treatment. Frozen Sections are a method that can assist the surgeon in intraoperative decision-making.